Get the Stockscreener App
6.13
3.20%
0.19
After Hours:
6.12
-0.010
-0.16%
Gyre Therapeutics Inc stock is traded at $6.13, with a volume of 43,077.
It is up +3.20% in the last 24 hours and down -2.54% over the past month.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
See More
Previous Close:
$5.94
Open:
$6.01
24h Volume:
43,077
Relative Volume:
0.47
Market Cap:
$683.43M
Revenue:
$117.05M
Net Income/Loss:
$-3.71M
P/E Ratio:
-78.69
EPS:
-0.0779
Net Cash Flow:
$1.67M
1W Performance:
+4.25%
1M Performance:
-2.54%
6M Performance:
-24.23%
1Y Performance:
-19.76%
1-Day Range:
$6.01
$6.27
1-Week Range:
$5.85
$6.27
52-Week Range:
$5.44
$9.42
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Name
Gyre Therapeutics Inc
Sector
Industry
Phone
(858) 284-0115
Address
12730 HIGH BLUFF DRIVE, SAN DIEGO
Compare GYRE vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
6.13 | 662.24M | 117.05M | -3.71M | 1.67M | -0.0779 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | Jefferies | Buy |
| Aug-26-25 | Initiated | H.C. Wainwright | Buy |
| Mar-11-25 | Initiated | Noble Capital Markets | Outperform |
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
View All
Gyre Therapeutics Inc Stock (GYRE) Latest News
Gyre Therapeutics Inc (GYRE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Gyre Therapeutics Inc (GYRE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Gyre Therapeutics Inc (GYRE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Gyre Therapeutics Inc (GYRE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GYRE|Gyre Therapeutics Inc|Price:5.940|Chg%:-0.070 - TradingKey
TradingKey - TradingKey
Cash flow from financing activities of Gyre Therapeutics Inc – GETTEX:L9S - TradingView
Gyre Therapeutics, Inc. Revenue Breakdown – NASDAQ:GYRE - TradingView
Gyre Therapeutics Inc (GYRE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Return on assets % of Gyre Therapeutics Inc – MUN:L9S - TradingView
Discontinued operations of Gyre Therapeutics Inc – MUN:L9S - TradingView
Return on assets % of Gyre Therapeutics Inc – GETTEX:A3EE5F - TradingView
Gyre Therapeutics Inc Statistics – MUN:L9S - TradingView
Gyre Therapeutics Inc Statistics – GETTEX:A3EE5F - TradingView
Gyre Therapeutics, Inc. (L9S.F) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Gyre Therapeutics Strengthens Board with New Director Appointments - The Globe and Mail
Gyre Therapeutics appoints three directors to board - Investing.com
Gyre Therapeutics (Nasdaq: GYRE) adds three directors, expanding expertise - Stock Titan
Gyre Therapeutics Appoints Three New Members to its Board of Directors - The Manila Times
Gyre Therapeutics, Inc. Announces Board and Committee Changes, Effective August 1, 2026 - marketscreener.com
Gyre Therapeutics Inc. (GYRE) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Surprise in Pre-Revenue StageNew Analyst Coverage - dars.gov.et
Gyre Therapeutics (GYRE) Registration filing Summary - Quartr
Cullgen $300M all-stock deal expands Gyre Therapeutics (Nasdaq: GYRE) - Stock Titan
Yue Xiong Net Worth (2026) - GuruFocus
Jialiang (nmn) Wang Net Worth (2026) - GuruFocus
Joshua Benjamin Bergmann Net Worth (2026) - GuruFocus
Form S-3/A Gyre Therapeutics Inc For: 13 July By Investing.com - Investing.com Nigeria
Gyre Therapeutics (Nasdaq: GYRE) details 31.3M-share resale and China risks - Stock Titan
GYRE Q1 2026 Earnings: Narrower-than-expected loss as EPS beats estimates; stock slipsEarnings Surprise Report - DonanımHaber
Gyre Therapeutics Q1 2026 Earnings: EPS Beats Estimates Despite Revenue Absence; Stock DeclinesReturn On Capital - DonanımHaber
Gyre Therapeutics highlights pipeline progress as investors watch fibrosis focus - ad-hoc-news.de
GYREGyre Therapeutics Inc Options - Finviz
Form 4 Gyre Therapeutics Inc For: 30 June By Investing.com - Investing.com Nigeria
Gyre Therapeutics (GYRE) director awarded 40,000 stock options at $5.95 - Stock Titan
Director Dan Weng receives 40,000-share option grant at GYRE (NASDAQ: GYRE) - Stock Titan
GYRE SEC FilingsGyre Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
US High Growth Tech Stocks to Watch - simplywall.st
Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Value Benchmark - marketscreener.com
GYRE THERAPEUTICS (GYRE): Kaskela Law LLC Announces Shareholder Investigation of Gyre Therapeutics and Encourages Long-Term GYRE Investors to Contact the Firm - ACCESS Newswire
Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Value-Defensive Index - marketscreener.com
Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Growth-Defensive Index - marketscreener.com
Gyre Therapeutics, Inc.(NasdaqCM: GYRE) added to Russell 2000 Defensive Index - marketscreener.com
Price to earnings forward of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView
Price to earnings forward of Gyre Therapeutics Inc – LS:A3EE5F - TradingView
Price to book forward of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView
Enterprise value to EBITDA forward of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView
Enterprise value to EBIT forward of Gyre Therapeutics Inc – TRADEGATE:L9S - TradingView
Price to earnings forward of Gyre Therapeutics Inc – TRADEGATE:L9S - TradingView
Gyre Therapeutics Inc (GYRE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Gyre Therapeutics Inc Actuals & Estimates (NASDAQ:GYRE) - TradingView
Enterprise value to revenue forward of Gyre Therapeutics, Inc. – NASDAQ:GYRE - TradingView
Gyre Therapeutics Inc Stock (GYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):